Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linjeta vs Regular Human Insulin in Type 1 Diabetes
NCT00542724Phase 3Completed
- Sponsor
- Biodel Inc.
- Start
- Sep 2006
- Primary completion
- Jul 2008
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, open-label trial of VIAject in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Biodel Inc. Primary endpoint: Change in Hemoglobin A1c at 6 months. Started Sep 2006; status: completed.
02
Drugs
VIAject
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00542724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542724.